Quince Therapeutics Inc (QNCX)

$1.23 0.00 (N/A)
Market Cap 20.05M
Revenue (ttm) 0.00
Net Income (ttm) -83.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.50
Volume 1,028,700
Avg Vol 7,118,305
Day's Range N/A - N/A
Shares Out 16.30M
Stochastic %K 17%
Beta 1.33
Analysts Hold
Price Target $6.50

Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an aut...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 910 5717
Address:
611 Gateway Boulevard, Suite 273, South San Francisco, United States
ShadowSnake
ShadowSnake Apr. 30 at 1:25 AM
$QNCX wen merger
1 · Reply
breadbaker007
breadbaker007 Apr. 30 at 1:17 AM
$QNCX regardless of QNCX reverse merging with Lighthouse or not, because Lighthouse just received $12 million in Series A funding yesterday, that greatly increases QNCX's 7.5% equity stake value and increases the probability of receiving $150 million in milestone obligations from Lighthouse. In conclusion, QNCX just became a more valuable shell for a reverse merger
0 · Reply
Bossymc
Bossymc Apr. 29 at 8:03 PM
$QNCX An entity knows something we dont....this is not a company that is about to crash! Do whats best for you. gl 😉
1 · Reply
Vivaelvino
Vivaelvino Apr. 29 at 8:01 PM
$QNCX very strange season today . Something is cocking behind the curtains, AH?
0 · Reply
Bossymc
Bossymc Apr. 29 at 7:28 PM
$QNCX For me I am observing the BUY side of the orderbook. Someone have been showing tremendous support at the 1.20 level. If I see this breaks and the BUY orders get thin, then its time for me to go....but for now it seems an entity knows something the rest of us doesn't. Gl 🤞🏼
1 · Reply
SpicyCaesar
SpicyCaesar Apr. 29 at 6:18 PM
$QNCX How much longer do you think we should hold onto this one for?
0 · Reply
Peaceouty
Peaceouty Apr. 29 at 6:10 PM
$QNCX WTF did Trump say today? Market is red as fuck.
0 · Reply
AlienTrador
AlienTrador Apr. 29 at 6:04 PM
$QNCX this is dead
0 · Reply
Peaceouty
Peaceouty Apr. 29 at 6:01 PM
$QNCX Please don’t break that 1.20 wall 😉
0 · Reply
WUXIANLONG
WUXIANLONG Apr. 29 at 5:32 PM
$QNCX 😡😡😡😡
0 · Reply
Latest News on QNCX
Quince Therapeutics Settles Approximately $16.4 Million of Debt

Mar 30, 2026, 8:30 AM EDT - 4 weeks ago

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks

Feb 12, 2026, 12:27 PM EST - 2 months ago

Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks

Quince Therapeutics Stock Explodes 300% On Strategic Review

Feb 10, 2026, 3:05 PM EST - 2 months ago

Quince Therapeutics Stock Explodes 300% On Strategic Review

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Feb 9, 2026, 4:05 PM EST - 2 months ago

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Jan 29, 2026, 3:10 PM EST - 3 months ago

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Jan 28, 2026, 4:05 PM EST - 3 months ago

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

Dec 15, 2025, 8:00 AM EST - 4 months ago

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

Dec 10, 2025, 4:05 PM EST - 5 months ago

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

Quince Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 10:30 AM EST - 5 months ago

Quince Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Quince Therapeutics to Participate at Investor Events in December 2025

Nov 24, 2025, 8:00 AM EST - 5 months ago

Quince Therapeutics to Participate at Investor Events in December 2025

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 4:05 PM EST - 6 months ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Nov 10, 2025, 4:05 PM EST - 6 months ago

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Oct 9, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Quince Therapeutics Transcript: Investor Day 2025

Oct 2, 2025, 10:00 AM EDT - 7 months ago

Quince Therapeutics Transcript: Investor Day 2025

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Sep 25, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Sep 11, 2025, 4:05 PM EDT - 8 months ago

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Quince Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 7:00 AM EDT - 8 months ago

Quince Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:05 PM EDT - 8 months ago

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:05 PM EDT - 9 months ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

Aug 7, 2025, 8:00 AM EDT - 9 months ago

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

OPCH

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jul 16, 2025, 8:00 AM EDT - 10 months ago

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Jul 10, 2025, 4:05 PM EDT - 10 months ago

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Jun 25, 2025, 4:05 PM EDT - 11 months ago

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Jun 18, 2025, 4:05 PM EDT - 11 months ago

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Jun 12, 2025, 5:15 PM EDT - 11 months ago

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jun 3, 2025, 4:05 PM EDT - 11 months ago

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Quince Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 3:30 PM EDT - 1 year ago

Quince Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

Quince Therapeutics to Present at Citizens Life Sciences Conference

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at Citizens Life Sciences Conference

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Apr 3, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Mar 24, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Quince Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 2:00 PM EST - 1 year ago

Quince Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Quince Therapeutics Transcript: Investor Update

Feb 7, 2025, 10:00 AM EST - 1 year ago

Quince Therapeutics Transcript: Investor Update

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Feb 7, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Feb 4, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Jan 28, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Jan 27, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Jan 23, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Nov 12, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Nov 11, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Quince Therapeutics Transcript: The ThinkEquity Conference 2024

Oct 30, 2024, 3:00 PM EDT - 1 year ago

Quince Therapeutics Transcript: The ThinkEquity Conference 2024

Quince Therapeutics Transcript: LD Micro Main Event XVII

Oct 29, 2024, 6:30 PM EDT - 1 year ago

Quince Therapeutics Transcript: LD Micro Main Event XVII

Quince Therapeutics to Participate at Upcoming Investor Conferences

Oct 14, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Participate at Upcoming Investor Conferences

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Jun 25, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Quince Therapeutics Transcript: The Citizens JMP Life Sciences Conference

May 13, 2024, 1:30 PM EDT - 2 years ago

Quince Therapeutics Transcript: The Citizens JMP Life Sciences Conference

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

May 6, 2024, 4:05 PM EDT - 2 years ago

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Quince Therapeutics Transcript: Study Update

Mar 26, 2024, 4:00 PM EDT - 2 years ago

Quince Therapeutics Transcript: Study Update

Quince Therapeutics Launches Scientific Advisory Board

Feb 22, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Launches Scientific Advisory Board

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Feb 15, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Quince Therapeutics Transcript: 7th Annual Neuroscience Innovation Forum

Jan 7, 2024, 4:30 PM EST - 2 years ago

Quince Therapeutics Transcript: 7th Annual Neuroscience Innovation Forum

Quince Therapeutics to Participate at Investor Events in January 2024

Jan 4, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Participate at Investor Events in January 2024

Quince Therapeutics Transcript: M&A Announcement

Jan 2, 2024, 6:00 PM EST - 2 years ago

Quince Therapeutics Transcript: M&A Announcement

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

ShadowSnake
ShadowSnake Apr. 30 at 1:25 AM
$QNCX wen merger
1 · Reply
breadbaker007
breadbaker007 Apr. 30 at 1:17 AM
$QNCX regardless of QNCX reverse merging with Lighthouse or not, because Lighthouse just received $12 million in Series A funding yesterday, that greatly increases QNCX's 7.5% equity stake value and increases the probability of receiving $150 million in milestone obligations from Lighthouse. In conclusion, QNCX just became a more valuable shell for a reverse merger
0 · Reply
Bossymc
Bossymc Apr. 29 at 8:03 PM
$QNCX An entity knows something we dont....this is not a company that is about to crash! Do whats best for you. gl 😉
1 · Reply
Vivaelvino
Vivaelvino Apr. 29 at 8:01 PM
$QNCX very strange season today . Something is cocking behind the curtains, AH?
0 · Reply
Bossymc
Bossymc Apr. 29 at 7:28 PM
$QNCX For me I am observing the BUY side of the orderbook. Someone have been showing tremendous support at the 1.20 level. If I see this breaks and the BUY orders get thin, then its time for me to go....but for now it seems an entity knows something the rest of us doesn't. Gl 🤞🏼
1 · Reply
SpicyCaesar
SpicyCaesar Apr. 29 at 6:18 PM
$QNCX How much longer do you think we should hold onto this one for?
0 · Reply
Peaceouty
Peaceouty Apr. 29 at 6:10 PM
$QNCX WTF did Trump say today? Market is red as fuck.
0 · Reply
AlienTrador
AlienTrador Apr. 29 at 6:04 PM
$QNCX this is dead
0 · Reply
Peaceouty
Peaceouty Apr. 29 at 6:01 PM
$QNCX Please don’t break that 1.20 wall 😉
0 · Reply
WUXIANLONG
WUXIANLONG Apr. 29 at 5:32 PM
$QNCX 😡😡😡😡
0 · Reply
bourock
bourock Apr. 29 at 4:37 PM
$QNCX Lighthouse announced they finished series A. I am not sure what it means for Qncx https://www.lighthousepharma.com/lighthousecloses12mfinancing
1 · Reply
breadbaker007
breadbaker007 Apr. 29 at 4:32 PM
$QNCX The chairman (David Lamond) owns 438,409 shares. You can bet he wants to see a return on his investment (i.e. reverse merger)
1 · Reply
Bossymc
Bossymc Apr. 29 at 4:01 PM
$QNCX Halted...News pending. Just kidding. 😂 trying to liven up the board.
1 · Reply
mpired
mpired Apr. 29 at 3:42 PM
$QNCX whats the plan here? offering for 30mil, then R/S, then keep milking investors with hopes until bankrupcy?
1 · Reply
CheckingMorons
CheckingMorons Apr. 29 at 3:13 PM
$QNCX the fuckers are diluting 60k sold now
0 · Reply
makesomemoneybro123
makesomemoneybro123 Apr. 29 at 2:29 PM
$QNCX what a shitty stock this one...
0 · Reply
breadbaker007
breadbaker007 Apr. 29 at 2:20 PM
$QNCX Volume seems very low today
0 · Reply
CheckingMorons
CheckingMorons Apr. 29 at 1:31 PM
$QNCX I hope they didn’t let this reset to 10 day above 1 so they can dilute more
0 · Reply
makesomemoneybro123
makesomemoneybro123 Apr. 29 at 1:31 PM
$QNCX What a shit... Not even 100k in volume
0 · Reply
Bottomdog
Bottomdog Apr. 29 at 12:32 PM
$XNDU $IQST $KLAR $QNCX $MRNO
1 · Reply
CheckingMorons
CheckingMorons Apr. 29 at 11:08 AM
$QNCX quince is so bad at releasing anything
0 · Reply
W2Cap
W2Cap Apr. 29 at 10:33 AM
$QNCX Need to get merger news out there ASAP if they have it. Saw someone saying after June 11 but shorts will pull this under 1 if that happens. Or at the very least provide some kind of update. Bios that don't communicate their plans get fucked up. Seen it plenty of times. Get the deal done.
1 · Reply